Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder

被引:114
作者
Freeman, MR
Yoo, JJ
Raab, G
Soker, S
Adam, RM
Schneck, FX
Renshaw, AA
Klagsbrun, M
Atala, A
机构
[1] BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA
[2] CHILDRENS HOSP, DEPT SURG RES, BOSTON, MA 02115 USA
[3] HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA
[4] HARVARD UNIV, SCH MED, DEPT SURG, BOSTON, MA 02115 USA
关键词
cell proliferation; urothelium; urinary tract; EGF receptor; ErbB; HER1;
D O I
10.1172/JCI119230
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The epidermal growth factor receptor (HER1) has been implicated in regenerative growth and proliferative diseases of the human bladder epithelium (urothelium), however a cognate HER1 ligand that can act as a growth factor for normal human urothelial cells (HUC) has not been identified, Here we show that heparin-binding EGF-like growth factor (HB-EGF), an activating HER1 ligand, is an autocrine regulator of HUC growth, This conclusion is based on demonstration of HB-EGF synthesis and secretion by primary culture HUC, identification of HER1 as an activatable HB-EGF receptor on HUC surfaces, stimulation of HUC clonal growth by HB-EGF, inhibition of HB-EGF-stimulated growth by heparin and of log-phase growth by CRM 197, a specific inhibitor of HB-EGF/HER1 interaction, and identification of human urothelium as a site of HB-EGF precursor (proHB-EGF) synthesis in vivo, ProHB-EGF expression was also detected in the vascular and detrusor smooth muscle of the human bladder, These data suggest a physiologic role for HB-EGF in the regulation of urothelial proliferation and regeneration subsequent to mucosal injury, Expression of proHB-EGF is also a feature of differentiated vascular and detrusor smooth muscle in the bladder, Because proHB-EGF is known to be the high affinity diphtheria toxin (DT) receptor in human cells, synthesis of the HB-EGF precursor by human urothelium also suggests the possibility of using the DT-binding sites of proHB-EGF as an in vivo target for the intraluminal treatment of urothelial diseases.
引用
收藏
页码:1028 / 1036
页数:9
相关论文
共 61 条